2194 Results for: "TMC HALLCREST"

Supplier: ENZO LIFE SCIENCES

Substrate for cathepsin H and aminopeptidases

Supplier: Apollo Scientific

H-Arg-AMC·2HCl

Supplier: Apollo Scientific

Boc-D-Tic-OH

Supplier: ENZO LIFE SCIENCES

Potent and selective inhibitor of GSK-3β (IC50=34nM). Stimulates glycogen synthesis in human liver cells and mimics other actions of insulin. Protects primary neurons from death induced by PI-3 kinase pathway inhibition suggesting therapeutic potential in neurodegenerative diseases and stroke. Reduces pulmonary inflammation and fibrosis in a mouse model.

Supplier: ENZO LIFE SCIENCES

CDK inhibitor

Supplier: ENZO LIFE SCIENCES

Inducer of intracellular ROS generation.

Supplier: ENZO LIFE SCIENCES

Metabolite of alprazolam.

Supplier: ENZO LIFE SCIENCES

Inhibitor of both Ca2+-dependent cytosolic cPLA2 (IC50=45 µM) and Ca2+-independent phospholipases A2 iPLA2 (IC50=3.8 µM).

Supplier: ENZO LIFE SCIENCES

PI3 kinase inhibitor

Supplier: ENZO LIFE SCIENCES

Methyltransferase inhibitor

Supplier: ENZO LIFE SCIENCES

Inhibits PKA (Ki=3.0μM), PKG (Ki=5.8μM), MLCK (Ki=97μM) and PKC (Ki=6μM). Also inhibits myosin light chain kinase. Induces apoptotic DNA fragmentation and cell death. Inhibits telomerase activity in treated NPC-076 cells. Cell permeable.

Supplier: ENZO LIFE SCIENCES

FAAH inhibitor

Supplier: ENZO LIFE SCIENCES

Inhibitor of a variety of serine/threonine and tyrosine kinases, like protein kinase C (PKC), cyclic AMP-dependent protein kinase (PKA), S6 kinase, Akt (protein kinase B; PKB), epidermal growth factor receptor (EGFR) tyrosine kinase activity and others including KDR, VEGFR, PDGFR, c-kit and other receptor tyrosine kinases. Potently inhibits FLT-3 kinase including mutant forms found in acute myeloid leukemia in vitro and in vivo. Apoptosis inducer. Showed broad antiproliferative activity against various tumor cell lines. Selectively inhibits T lymphocyte production of TNF-α. Upregulates endothelial nitric oxide synthase (eNOS; NOS III). Abrogates tumor angiogenesis in vivo.

Supplier: ENZO LIFE SCIENCES

Glucocorticoid receptor ligand

Supplier: ENZO LIFE SCIENCES

Prostanoid receptor ligand.

Supplier: ENZO LIFE SCIENCES

Caspase-1 inhibitor

Supplier: ENZO LIFE SCIENCES

HMG-CoA reductase inhibitor

Supplier: ENZO LIFE SCIENCES

Mixture of alamethicin homologs. Membrane permeabilizing antibiotic. Applications include increasing [32P] incorporation into phosphatidylinositol 4-phosphate and permeabilization of sarcoplasmic reticulum vesicles. Causes fusion of lipid vesicles.

Supplier: ENZO LIFE SCIENCES

Lipoxygenase inhibitor

Supplier: Apollo Scientific

Fmoc-Tic-OH

Supplier: ENZO LIFE SCIENCES

Calpain and cathepsin inhibitor

Supplier: ENZO LIFE SCIENCES

TRPV1 agonist

Supplier: ENZO LIFE SCIENCES

Organic vanadium complex which acts as a potent insulin mimic.

Supplier: ENZO LIFE SCIENCES

Ras farnesyltransferase inhibitor. Induces tumor regression in transgenic mice with multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Induces p21 expression and arrests cells at G1. Causes enhanced mitotic sensitivity to taxol.

Supplier: ENZO LIFE SCIENCES

Endogenous [1] ligand for the CB1 receptor (CB1: Ki=52nm; CB2: Ki=1930nm [2]) and TRPV1 (Ki=5.78µM [3,4]). Inhibits NF-κB activation through direct binding to IKKβ [5] and induces apoptosis independently of cannabinoid or vanilloid receptors [6]. Activates the MAP kinase (MAPK/ERK) signalling pathway [7].

Supplier: ENZO LIFE SCIENCES

HAT inhibitor

Supplier: ENZO LIFE SCIENCES

Antioxidant and chemopreventive

Supplier: ENZO LIFE SCIENCES

Cannabinoid receptor ligand.

Supplier: ENZO LIFE SCIENCES

ADP-ribosylation factor inhibitor

Supplier: ENZO LIFE SCIENCES

Endogenous cannabinoid. Weak ligand of CB1 (Ki=23.8µM) and CB2 (Ki=13.9µM) receptor. Inhibits fatty acid amide hydrolase (FAAH) (IC50=5.1µM). Immunosuppressant, anti-inflammatory, anti-nociceptive and anti-convulsant in vivo. The exact mode of action has not yet been revealed. It has been suggested that PEA: i) binds to a yet to be discovered cannabinoid receptor similar to CB2; ii) administered in vivo elicits the synthesis of endogenous agonists of CB2; iii) acts as an "entourage" compound by enhancing the activity and/or by influencing the turnover of endogenous agonists of CB2, possibly but not uniquely, by inhibiting their degradation.